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Necrobiotic xanthogranuloma (NXG) is a rare destructive xanthomatous granuloma with chronic, indolent, and progressive
course. The morbidity and mortality are the results from wound complications and associated disorders. Because of its strong
association with monoclonal gammopathy and multiple myeloma, early recognition of disease is mandatory to monitor and
prevent systemic involvements of hematologic malignancies.
1.Introduction
Necrobiotic xanthogranuloma (NXG) is a rare nonLanger-
hans cell histiocytosis. Approximately 100 cases have been
reported worldwide [1]. Clinically, it is characterized by
multiple yellowish to reddish-brown nodules and plaques
develop on periorbital regions, trunk, and extremities.
Most lesions are asymptomatic but sometimes may ulcerate
(40–50% of cases). Hematologic malignancy is the most
important associated ﬁndings. Monoclonal gammopathies
are found in 80–90% of cases [2–5].
On microscopic examination, it is characterized by the
extensive area of necrobiosis surrounded with granuloma-
tous inﬁltration from dermis to subcutis. Bizarre giant cells,
Touton giant cells, foamy histiocytes, and cholesterol clefts
are frequently found in necrobiotic area [6–8].
Necrobiotic xanthogranuloma may be diﬃcult to diag-
nosebecauseitisoftenasymptomaticandslowlyprogressive.
If the patients present with only periorbital lesions, they
may be misdiagnosed as xanthelasma and may not receive
proper investigations and/or schedule followup for hemato-
logic malignancies. In addition, surgical treatment in these
patients may cause more complications.
Therefore, it is important to recognize the course of this
rare disease in order to plan for long-term management and
f o l l o w u p .E a r l yd e t e c t i o no fs y s t e m i ci n v o l v e m e n t so fe i t h e r
hematologic malignancies or necrobiotic xanthogranuloma
itself is necessary.
2.CaseReport
A 64-year-old woman presented with a 7-year history of
multiple asymptomatic yellowish to reddish-brown nodules
and plaques gradually occurred on both legs and arms. Few
asymptomatic periorbital lesions had developed for the last
few years. The ﬁrst clinical impression was xanthelasma and
granuloma annulare. Initial excisional biopsy was performed
and diagnosed as subcutaneous granuloma annulare. Other
investigations were done and showed hypercholesterolemia
that was eﬀectively controlled by lipidlowering agents. Some
lesions were treated with intralesional and topical corticos-
teroidswithoutanyclinicalimprovement.Thesecondbiopsy
wasthenperformedandadiagnosisofxanthogranulomawas
established. The lesions located on her both forearms, legs,
and periorbital regions have progressively enlarged. Later on,
the patient was referred to our hospital for dermatologic
consultation.
Physical examination showed multiple yellowish to
reddish-brown nodules and plaques on face and extremities
(Figures 1(a) and 1(b)). Some lesions were observed to
have central ulceration and atrophy distributed on her
legs and forearms (Figure 1(c)), healing with scar. The2 Dermatology Research and Practice
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Figure 1: Physical examination demonstrated multiple yellowish to reddish-brown nodules and plaques on face (a) and extremities (b).
Some lesions were observed to have central ulceration and atrophy (c).
(a) (b)
(c) (d)
Figure 2: Histopathology (Hematoxylin & Eosin staining) revealed diﬀuse inﬁltration from papillary dermis to superﬁcial subcutaneous fat
by mononuclear cells (H&Ex12.5) (a). Palisaded granuloma with necrobiosis is also noted (H&Ex200) (b). Xanthoma cells and Touton giant
cells (c) and cholesterol clefts (d) are seen (H&Ex400).
provisional diﬀerential diagnoses included necrobiotic xan-
thogranuloma, atypical necrobiotic lipoidica, and diﬀuse
plane xanthoma.
Skin biopsy was again performed and revealed palisaded
granulomascontainingforeignbodytype,Toutongiantcells,
foamy histiocytes, surrounding large necrobiotic areas that
extended from the dermis to subcutis. Cholesteral clefts
were found in the center of necrobiotic area (Figure 2). The
ﬁndings previously described were favorable of necrobiotic
xanthogranuloma (NXG).
When NXG was diagnosed, other investigations for un-
derlying hematologic malignancies were performed. Ser-
um protein electrophoresis demonstrated monoclonal spike
in gammaglobulin region, suggesting monoclonal gam-
mopathy. Immunoelectrophoresis also showed IgG lam-bda
monoclonal gammopathy. There was no osteolytic lesion in
bone survey. Lastly, bone marrow study was compatible with
multiple myeloma.
In this patient, the ﬁnal diagnosis was NXG associ-
atied with asymptomatic multiple myeloma. AppropriateDermatology Research and Practice 3
treatments for this condition included long-term closed
followup for early detection of systemic involvements from
multiple myeloma and necrobiotic xanthogranuloma itself.
Intralesional corticosteroids have been employed to treat
cutaneous lesions with mild clinical improvement.
3. Discussion
Necrobiotic xanthogranuloma (NXG) is a rare disorder,
approximately 100 cases reported in the literature [1]. It
is a chronic, progressive, multiorgan involved disease of
unknown etiology [8]. Pathogenesis is still unclear. Age of
onset is average at the sixth decade ranging from 17–85 years
without sex predilection [3, 4]. NXG is clinically character-
ized by multiple yellowish to reddish brown nodules which
slowly enlarge into plaques with yellowish hue and telangiec-
tasia. 43% of cases developed central atrophy and ulceration.
The most common site of involvement is the face
especially periorbital areas (85% of cases) [3, 4]. Most of the
skin lesions initially present on the extremities or trunk [2].
The lesions are varying in size ranging from 0.5 to 20cm.
Oral mucosal lesions may be presented [9]. The periorbital
lesions are the most characteristic sign in this condition
starting with xanthelasma-like papules which progress into
plaques. Most of cutaneous lesions are asymptomatic, but
painful or burning sensation may be observed.
Ophthalmologic manifestations can be seen in 50–
80% of cases including conjunctival, corneal, and scleral
involvements. Orbital masses and periorbital edema from
xanthomatous inﬂammation of periorbital tissue have been
reported [2, 10]. Magnetic resonance and axial computed
tomography may be necessary in some patients to demon-
strate ocular involvement.
NXG is now considered as a systemic disease. Internal
organ involvements have been reported including spleen,
heart, lung, kidney, intestine, ovary, larynx, pharynx, skeletal
muscles, and the central nervous system. Lymphadenopathy
is occasionally presented [3–5, 8, 11]. However, internal
organ involvements in most cases are asymptomatic and
diagnosis is established only in postmortem biopsy.
Hematologic and lymphoproliferative malignancies are
the most important associated systemic disorders which
develop approximately 2.4 years after the onset of skin
lesions [1]. 80–90% of cases demonstrate monoclonal
gammopathy (IgG Kappa for 60% and IgG Lambda for
26%); however, only 10% of cases will develop multiple
myeloma [2, 12]. Other related conditions that can be
found with NXG included Hodgkin’s disease, non-Hodgkin’s
lymphoma, chronic lymphocytic leukemia, myelodysplas-
tic syndrome, macroglobulinemia, cryoglobulinemia, and
amyloidosis. Incisional biopsy is recommended in every
suspiciouspatienttoestablishthediagnosisalthoughtherisk
of wound complications is increased in NXG [8].
Histopathologic diﬀerential diagnoses include dissimi-
lar diseases that can possess both necrobiotic areas and
granulomas such as granuloma annulare (GA), necrobiotic
lipoidica (NL), palisaded neutrophilic dermatosis (PND),
and rheumatoid nodule (RN). Necrobiotic xanthogranu-
loma (NXG) diﬀers from GA, NG, PND, and RN by the
presence of prominent necrobiosis and often accumulating
into large areas. Touton and foreign body type giant cells and
cholesterol clefts are also obvious. In GA, the necrobiosis is
usuallyfocalandsmallerandoftencontainslessToutongiant
cells and cholesterol clefts located in upper and mid-dermis.
In NL, the necrobiotic areas are elongated, usually arranging
in the step-ladder, horizontal orientation. PND and RN can
be distinguished easily from NXG because of the presence of
innumerable neutrophils in the inﬁltrate in the former and
deposition of ﬁbrin inside the necrobiotic areas in the latter.
Necrobiotic areas surrounded by granulomas in GA,
PND, NL, and NXG can be found broadly from dermis to
subcutis, while the necrobiotic areas in GA are always accu-
mulated in focal area surrounded by lymphocytes and giant
cells. In PND, neutrophils must be predominantly found.
And multiple areas of palisaded granulomas distributing in
horizontal orientation are characteristics of NL. Therefore,
the diagnosis of GA, PND, and NL should be excluded.
In NXG, the large necrobiotic area, Touton giant cells and
cholesterol cleft can always be found, but rarely in NL. And
this patient should be diagnosed as NXG.
Diﬀuse plane xanthoma (DPX) was one of the clinical
diﬀerential diagnoses in this patient. Histological examina-
tion of DPX should reveal large sheets and clusters of foamy
cells, single and in small groups, diﬀusely scattered through-
out the dermis, occasionally they may appear predominantly
in a perivascular location [13]. Touton giant cells are rarely
present in DPX. Histopathologic features observed in our
case are not consistent with those in DPX.
The clinical course of NXG is often chronic, progressive,
and indolent. The prognosis is uncertain but generally good,
depending on the severity of extracutaneous involvements,
the presence of visceral malignancies, and wound complica-
tions. Patients should undergo for long-term periodic exam-
ination for hematologic and other associated malignancies
[5, 9, 14]. Multiple myeloma developing in the patients with
NXG seems to present with a relatively benign behavior.
Ugurluetal.foundthat100%and90%ofpatientswithNXG
and multiple myeloma could survive at least 10 and 15 years,
respectively [2–4].
Currently, there are no randomizedcontrolled studies for
therapeutic regimens. Chemotherapy is the most frequently
used treatment and generally eﬀective in modifying a disease
course. Chlorambucil appears to be the most eﬀective
treatment for patients with extensive cutaneous lesions [15–
17]. Other systemic agents have been employed with some
improvement including systemic steroid [18, 19], chloram-
bucil plus systemic corticosteroids, [7] cyclophosphamide,
[20] melphalan, [21, 22] melphalan plus systemic corticos-
teroids, [23–25] azathioprine plus systemic corticosteroids,
[26] thalidomide [27], and interferon-α2b [7, 28]. All
treatments can produce remission of paraproteinemia as
well as skin lesions but, unfortunately, cannot prevent the
evolution to multiple myeloma.
Elners and coworkers demonstrated that intralesional
injection of triamcinolone acetonide was eﬀective and safe
treatment for orbital NXG in adults [29]. Surgical excision
maybebeneﬁtsforlocalizedcutaneouslesions,exceptlesions4 Dermatology Research and Practice
on periorbital area, because of high rate of recurrence,
stimulation of lesional activity, and scar formation resulting
in eyelids retraction. Cryotherapy and radiotherapy have
been tried without satisﬁed results. Thalidomide may be an
interesting option for recalcitrant skin lesions [12, 27].
In our patient, monoclonal gammopathy has been
detected after cutaneous manifestations for 7 years without
symptomatic multiple myeloma or other systemic involve-
ments. However, life-long, physical examination, and labo-
ratory investigations for malignancy surveillance should be
performed periodically.
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